Asia Pacific Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Country and Growth Forecast, 2022

List of Tables

The Asia Pacific Bronchodilators Market would witness market growth of 4.6% CAGR during the forecast period (2022-2028).

The bronchodilators come in two forms which are short-acting and long-acting bronchodilators. Short-acting bronchodilators stop or provide relief from sudden symptoms of asthma quickly. They are effective for three to six hours. They are also known as a rescue inhaler. Inhalers are canisters of medicine in a plastic holder with a mouthpiece.

The steps theory in managing reversible lung diseases like asthma incorporates long- and short-acting bronchodilators. Those with intermittent asthma should get a short-acting bronchodilator like albuterol as per requirement. For more symptomatic disease, adding a low-dose inhaled corticosteroid is generally the next step, followed by adding a long-acting bronchodilator with the inhaled steroid. The increment in the aggressive treatment should differ from those who specialize in allergy and asthma treatment.

After achieving control, the patient can consult with their doctor to change these medications to a smaller dose with fewer adverse effects. Failure to control symptoms with short or long-acting corticosteroids and bronchodilators can cause irreversible lung injury. Frequent monitoring through pulmonary function tests and peak airway flow is essential for the success of the treatment.

China is the biggest consumer and producer of tobacco globally. There are more than 300 million smokers in China, which is around one-third of the world's total. In China, more than half of adult men are tobacco smokers. About one in every three cigarettes smoked is in China. In addition, over 700 million non-smokers in China, including 180 million children, are exposed to second-hand smoke at least once a day a week. The high level of tobacco consumption will increase the number of respiratory cases and the utilization of bronchodilators medication, thus propelling the market growth in the region.

The China market dominated the Asia Pacific Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,709.1 million by 2028. The Japan market is registering a CAGR of 4% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 5.2% during (2022 - 2028).

Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

Beta-Adrenergic
Xanthine Derivatives
Anticholinergic

By Route of Administration

Nasal (Inhalable)
Oral
Injectable

By Disease

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Others

By Country

China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

Companies Profiled

Glenmark Pharmaceuticals Limited
Merck & Co., Inc.
GlaxoSmithKline PLC
AstraZeneca PLC
Teva Pharmaceuticals Industries Ltd.
Cipla Limited
Viatris, Inc.
Novartis AG
Boehringer Ingelheim International GmbH
Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Asia Pacific Bronchodilators Market, by Drug Class
- 1.4.2 Asia Pacific Bronchodilators Market, by Route of Administration
- 1.4.3 Asia Pacific Bronchodilators Market, by Disease
- 1.4.4 Asia Pacific Bronchodilators Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Asia Pacific Bronchodilators Market by Drug Class

3.1 Asia Pacific Beta-Adrenergic Market by Country
3.2 Asia Pacific Xanthine Derivatives Market by Country
3.3 Asia Pacific Anticholinergic Market by Country

Chapter 4. Asia Pacific Bronchodilators Market by Route of Administration

4.1 Asia Pacific Nasal (Inhalable) Market by Country
4.2 Asia Pacific Oral Market by Country
4.3 Asia Pacific Injectable Market by Country

Chapter 5. Asia Pacific Bronchodilators Market by Disease

5.1 Asia Pacific Asthma Market by Country
5.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 Asia Pacific Others Market by Country

Chapter 6. Asia Pacific Bronchodilators Market by Country

6.1 China Bronchodilators Market
- 6.1.1 China Bronchodilators Market by Drug Class
- 6.1.2 China Bronchodilators Market by Route of Administration
- 6.1.3 China Bronchodilators Market by Disease
6.2 Japan Bronchodilators Market
- 6.2.1 Japan Bronchodilators Market by Drug Class
- 6.2.2 Japan Bronchodilators Market by Route of Administration
- 6.2.3 Japan Bronchodilators Market by Disease
6.3 India Bronchodilators Market
- 6.3.1 India Bronchodilators Market by Drug Class
- 6.3.2 India Bronchodilators Market by Route of Administration
- 6.3.3 India Bronchodilators Market by Disease
6.4 South Korea Bronchodilators Market
- 6.4.1 South Korea Bronchodilators Market by Drug Class
- 6.4.2 South Korea Bronchodilators Market by Route of Administration
- 6.4.3 South Korea Bronchodilators Market by Disease
6.5 Singapore Bronchodilators Market
- 6.5.1 Singapore Bronchodilators Market by Drug Class
- 6.5.2 Singapore Bronchodilators Market by Route of Administration
- 6.5.3 Singapore Bronchodilators Market by Disease
6.6 Malaysia Bronchodilators Market
- 6.6.1 Malaysia Bronchodilators Market by Drug Class
- 6.6.2 Malaysia Bronchodilators Market by Route of Administration
- 6.6.3 Malaysia Bronchodilators Market by Disease
6.7 Rest of Asia Pacific Bronchodilators Market
- 6.7.1 Rest of Asia Pacific Bronchodilators Market by Drug Class
- 6.7.2 Rest of Asia Pacific Bronchodilators Market by Route of Administration
- 6.7.3 Rest of Asia Pacific Bronchodilators Market by Disease

Chapter 7. Company Profiles

7.1 Glenmark Pharmaceuticals Limited
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Research & Development Expenses
- 7.1.4 Recent strategies and developments:
  - 7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental and Regional Analysis
- 7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental and Regional Analysis
- 7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.4 Research & Development Expenses
7.6 Cipla Limited
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expense
7.8 Novartis AG
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Regional & Segmental Analysis
- 7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Regional & Segmental Analysis
- 7.10.4 Research & Development Expenses

LIST OF TABLES

TABLE 1 Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Anticholinergic Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Anticholinergic Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 21 Asia Pacific Asthma Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific Asthma Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
TABLE 25 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 26 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 27 Asia Pacific Bronchodilators Market by Country, 2018 - 2021, USD Million
TABLE 28 Asia Pacific Bronchodilators Market by Country, 2022 - 2028, USD Million
TABLE 29 China Bronchodilators Market, 2018 - 2021, USD Million
TABLE 30 China Bronchodilators Market, 2022 - 2028, USD Million
TABLE 31 China Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 32 China Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 33 China Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 34 China Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 35 China Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 36 China Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 37 Japan Bronchodilators Market, 2018 - 2021, USD Million
TABLE 38 Japan Bronchodilators Market, 2022 - 2028, USD Million
TABLE 39 Japan Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 40 Japan Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 41 Japan Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 Japan Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 Japan Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 44 Japan Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 45 India Bronchodilators Market, 2018 - 2021, USD Million
TABLE 46 India Bronchodilators Market, 2022 - 2028, USD Million
TABLE 47 India Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 48 India Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 49 India Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 50 India Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 51 India Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 52 India Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 53 South Korea Bronchodilators Market, 2018 - 2021, USD Million
TABLE 54 South Korea Bronchodilators Market, 2022 - 2028, USD Million
TABLE 55 South Korea Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 56 South Korea Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 57 South Korea Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 58 South Korea Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 59 South Korea Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 60 South Korea Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 61 Singapore Bronchodilators Market, 2018 - 2021, USD Million
TABLE 62 Singapore Bronchodilators Market, 2022 - 2028, USD Million
TABLE 63 Singapore Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 64 Singapore Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 65 Singapore Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Singapore Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Singapore Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 68 Singapore Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 69 Malaysia Bronchodilators Market, 2018 - 2021, USD Million
TABLE 70 Malaysia Bronchodilators Market, 2022 - 2028, USD Million
TABLE 71 Malaysia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 72 Malaysia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 73 Malaysia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 74 Malaysia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 75 Malaysia Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 76 Malaysia Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 77 Rest of Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
TABLE 78 Rest of Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
TABLE 79 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 80 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 81 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Rest of Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 84 Rest of Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 85 Key Information - Glenmark Pharmaceuticals Limited
TABLE 86 KEY INFORMATION - Merck & Co., Inc.
TABLE 87 Key Information - GlaxoSmithKline PLC
TABLE 88 KEY INFORMATION - AstraZeneca PLC
TABLE 89 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 90 Key Information - Cipla Limited
TABLE 91 key information - Viatris, Inc.
TABLE 92 Key Information - Novartis AG
TABLE 93 Key Information - Boehringer Ingelheim International GmbH
TABLE 94 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

FIG 1 Methodology for the research

Asia Pacific Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Country and Growth Forecast, 2022 - 2028

Description

Table of Contents